129 related articles for article (PubMed ID: 7824511)
21. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
Flørenes VA; Maelandsmo GM; Forus A; Andreassen A; Myklebost O; Fodstad O
J Natl Cancer Inst; 1994 Sep; 86(17):1297-302. PubMed ID: 8064888
[TBL] [Abstract][Full Text] [Related]
22. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
Schneider-Stock R; Walter H; Radig K; Rys J; Bosse A; Kuhnen C; Hoang-Vu C; Roessner A
J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
[TBL] [Abstract][Full Text] [Related]
23. p53 mutations in Hodgkin's disease.
Chen WG; Chen YY; Kamel OW; Koo CH; Weiss LM
Lab Invest; 1996 Oct; 75(4):519-27. PubMed ID: 8874383
[TBL] [Abstract][Full Text] [Related]
24. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.
Oda H; Nakatsuru Y; Ishikawa T
Cancer Res; 1995 Feb; 55(3):658-62. PubMed ID: 7834636
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.
Hall KL; Teneriello MG; Taylor RR; Lemon S; Ebina M; Linnoila RI; Norris JH; Park RC; Birrer MJ
Gynecol Oncol; 1997 May; 65(2):330-5. PubMed ID: 9159347
[TBL] [Abstract][Full Text] [Related]
26. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
Perry ME; Levine AJ
Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
[TBL] [Abstract][Full Text] [Related]
27. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions.
Ahomadegbe JC; Barrois M; Fogel S; Le Bihan ML; Douc-Rasy S; Duvillard P; Armand JP; Riou G
Oncogene; 1995 Mar; 10(6):1217-27. PubMed ID: 7700647
[TBL] [Abstract][Full Text] [Related]
28. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
29. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.
Bardeesy N; Falkoff D; Petruzzi MJ; Nowak N; Zabel B; Adam M; Aguiar MC; Grundy P; Shows T; Pelletier J
Nat Genet; 1994 May; 7(1):91-7. PubMed ID: 8075648
[TBL] [Abstract][Full Text] [Related]
30. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
31. P53 mutations in Ewing's sarcoma.
Park YK; Chi SG; Kim YW; Park HR; Unni KK
Oncol Rep; 2001; 8(3):533-7. PubMed ID: 11295075
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutation in primary human renal cell carcinoma.
Torigoe S; Shuin T; Kubota Y; Horikoshi T; Danenberg K; Danenberg PV
Oncol Res; 1992; 4(11-12):467-72. PubMed ID: 1299377
[TBL] [Abstract][Full Text] [Related]
33. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas.
Waber PG; Chen J; Nisen PD
Cancer Res; 1993 Dec; 53(24):6028-30. PubMed ID: 8261417
[TBL] [Abstract][Full Text] [Related]
34. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.
Hollstein M; Marion MJ; Lehman T; Welsh J; Harris CC; Martel-Planche G; Kusters I; Montesano R
Carcinogenesis; 1994 Jan; 15(1):1-3. PubMed ID: 8293534
[TBL] [Abstract][Full Text] [Related]
35. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
[TBL] [Abstract][Full Text] [Related]
37. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas.
Ohnishi H; Kawamura M; Hanada R; Kaneko Y; Tsunoda Y; Hongo T; Bessho F; Yokomori K; Hayashi Y
Genes Chromosomes Cancer; 1996 Mar; 15(3):187-90. PubMed ID: 8721685
[TBL] [Abstract][Full Text] [Related]
38. Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis.
Suzuki Y; Tamura G; Satodate R; Fujioka T
Jpn J Cancer Res; 1992 Mar; 83(3):233-5. PubMed ID: 1582882
[TBL] [Abstract][Full Text] [Related]
39. Low incidence of point mutations detected in the p53 tumor suppressor gene from chemically induced rat renal mesenchymal tumors.
Weghorst CM; Dragnev KH; Buzard GS; Thorne KL; Vandeborne GF; Vincent KA; Rice JM
Cancer Res; 1994 Jan; 54(1):215-9. PubMed ID: 8261441
[TBL] [Abstract][Full Text] [Related]
40. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.
Schiebe M; Ohneseit P; Hoffmann W; Meyermann R; Rodemann HP; Bamberg M
J Neurooncol; 2000 Sep; 49(3):197-203. PubMed ID: 11212898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
